For pharmaceutical products, medical devices, biologics, and tissue products intended for human or animal use, sterility is the ultimate quality attribute — and sterility testing is the regulatory gate through which every affected product batch must pass before release. Failure to demonstrate sterility means mandatory batch rejection, with all the financial, operational, and reputational consequences that entails.
Governed in the United States by USP General Chapter <71> and harmonized internationally with European Pharmacopoeia (EP) Chapter 2.6.1 and the Japanese Pharmacopoeia (JP), sterility testing requires highly stringent aseptic conditions, validated methodology, and meticulous execution. A valid sterility test is not simply a matter of culturing samples — it requires upfront proof that the test system itself is capable of detecting contamination in the specific product matrix being tested.
This guide provides a technical overview of the complete sterility testing framework: which products require testing, the two compendial methods under USP <71>, method validation through bacteriostasis and fungistasis (B&F) testing, the distinction between sterility testing and bioburden testing, emerging rapid methods, the environmental requirements for testing, and how to select and work with an accredited contract sterility testing laboratory.
Which Products Require Sterility Testing?
USP <71> applies to all pharmaceutical products and medical articles that are labeled as sterile and intended for application to body surfaces, mucous membranes, or parenteral administration. The requirement extends broadly across several product categories:
- Parenteral drugs. All injectable products — intravenous (IV) solutions, intramuscular injections, subcutaneous injections, intrathecal drugs — must be sterile. This is the largest and most critical category. Large-volume parenterals (LVPs, >100 mL) and small-volume parenterals (SVPs, ≤100 mL) have different test quantity requirements under USP <71>.
- Ophthalmic products. Eye drops, eye ointments, and intraocular preparations contact sensitive tissue and must be sterile.
- Sterile powders and lyophilized products. Lyophilized (freeze-dried) drug products reconstituted for injection must be sterile before and after reconstitution.
- Medical devices. Devices contacting sterile body spaces — implants, catheters, surgical instruments, stents, wound dressings — require sterility testing. Direct inoculation is typically the method of choice for devices, as the intact device or relevant portions can be immersed in culture media.
- Biologics and advanced therapy medicinal products (ATMPs). Monoclonal antibodies, cell therapies, gene therapies, and vaccine products all require sterility testing. The short shelf lives of many ATMPs (hours to days) create significant pressure for faster testing turnaround, driving interest in rapid alternative methods.
- Compounded sterile preparations. Compounding pharmacies producing sterile preparations under USP <797> are subject to sterility testing requirements, including environmental monitoring programs.
- Radiopharmaceuticals. Although the 14-day incubation period typically exceeds the product shelf life, sterility testing is still required — results are often retrospective for short-lived radiolabeled products.
- Tissue products and regenerative medicine. Human tissue-based products regulated by the FDA are subject to sterility requirements and testing under 21 CFR Part 1271.
Regulatory Framework: USP <71>, EP 2.6.1, and JP
The three major compendial sterility testing chapters — USP <71>, EP 2.6.1, and JP — have been subject to international harmonization under the Pharmacopoeial Discussion Group (PDG) since 2002, and their core requirements are now substantially aligned. All three mandate the same two testing methods (membrane filtration and direct inoculation), the same two culture media (FTM and SCDM/TSB), the same 14-day minimum incubation period, and the same requirement for method suitability (B&F) testing before routine use.
Minor procedural differences remain between the compendia — particularly around sampling tables (minimum number of items to test per batch size), specific diluting fluid compositions, and incubation temperature tolerances — and manufacturers operating across multiple regulatory territories must ensure their methods comply with all applicable compendia. Regulatory submissions to FDA, EMA, and PMDA require sterility testing data generated under the applicable compendial chapter for that market.
The FDA’s guidance for industry on sterile drug products produced by aseptic processing provides additional context on how sterility testing fits within the broader current Good Manufacturing Practice (cGMP) framework, including the important principle that sterility testing alone does not — and cannot — assure that a product or batch is sterile. Sterility is primarily assured through validated sterilization processes or validated aseptic processing; the compendial sterility test is a confirmatory quality check, not the primary sterility assurance mechanism.
The Common Foundation: Culture Media and Incubation Conditions
Regardless of whether membrane filtration or direct inoculation is used, all USP <71> sterility testing relies on the same two culture media and defined incubation conditions. These are mandated by the compendium to ensure that the widest possible spectrum of aerobic, anaerobic, and fungal contaminants can be detected.
Soybean-Casein Digest Medium (SCDM) / Tryptic Soy Broth (TSB)
SCDM — also called Tryptic Soy Broth or TSB — is a highly nutritious, aerobic medium designed to support the growth of aerobic bacteria and fungi, including yeasts and molds. It is incubated at 20°C to 25°C for the full 14-day period. This temperature range is optimized for fungal growth, which tends to be slower and requires the cooler end of the incubation temperature spectrum.
Fluid Thioglycollate Medium (FTM)
FTM is specifically formulated to support the growth of anaerobic bacteria — organisms that are killed by oxygen and therefore cannot grow in aerobic media. The thioglycollate and other reducing agents in the medium create a low-oxygen gradient: aerobes grow in the oxygen-rich upper portion of the tube, while strict anaerobes grow in the oxygen-depleted lower portion, and microaerophilic organisms colonize the middle zone. FTM is incubated at 30°C to 35°C, the optimal temperature range for bacterial growth.
Incubation and observation
All containers must be incubated for a minimum of 14 days — a requirement driven by the biology of slow-growing organisms such as fungi and certain anaerobes, which may require extended incubation to produce visible turbidity. Cultures are examined visually at multiple intervals during incubation (typically days 3, 5, 7, and 14) for macroscopic evidence of growth, which manifests as turbidity or cloudiness of the previously clear medium. A culture that remains clear throughout the full 14-day period and shows no evidence of growth constitutes a passing sterility test result.
Comparing the Two Compendial Methods: Direct Inoculation vs. Membrane Filtration
| Criterion | Direct inoculation | Membrane filtration |
| Mechanism | Test article added directly into culture medium vessels | Test article passed through ≤0.45 μm sterile membrane; membrane transferred to media |
| Best suited for | Viscous products (oils, ointments, suspensions); medical devices; products not amenable to filtration | Aqueous solutions; large-volume parenterals; products with antimicrobial properties |
| Antimicrobial products | Significant limitation — preservatives, antibiotics, or bacteriostatic agents in the product can suppress growth, causing false-negative results | Lower — physical separation from the inhibitory matrix greatly reduces risk |
| Sample volume | Limited — product volume must not exceed 10% of total media volume to prevent dilution of growth promotion capacity | Higher volumes testable — entire large-volume product can be concentrated on the membrane |
| Medical devices | Method of choice — intact device or relevant portions immersed directly in media throughout 14-day incubation | Less suitable for solid devices; occasionally used for device rinse fluids |
| Technical complexity | Lower — fewer steps; simpler equipment | Higher — sterile filter assemblies, validated rinsing protocol, inactivating agent selection |
| Regulatory preference | Acceptable when filtration is not feasible | Gold standard; preferred by regulators when product characteristics permit |
| Risk of false negative | Higher — for products with antimicrobial activity without proper neutralization | Higher volumes testable — the entire large-volume product can be concentrated on the membrane |
Part I: The Direct Inoculation Method
Direct inoculation involves the aseptic transfer of a defined volume of the test article into vessels of each culture medium. The ratio of sample to medium volume is regulated by USP <71> to ensure that the product does not exert bacteriostatic or fungistatic effects at the dilution achieved — generally, the product volume must not exceed 10% of the total medium volume unless otherwise justified.
For medical devices, the entire device — or for large devices, those portions that contact the patient — is immersed directly in sufficient medium to achieve complete contact throughout the 14-day incubation period. This approach is uniquely well-suited to devices because the organism-to-device interface is continuously maintained, maximizing detection sensitivity for surface contamination.
The critical limitation of direct inoculation is antimicrobial interference. Pharmaceutical formulations routinely contain bacteriostatic preservatives (benzalkonium chloride, thiomersal, parabens), antibiotics, or other antimicrobial components that can suppress or eliminate any contaminating organisms introduced into the test medium — producing a clear, growth-free culture that passes the sterility test even when the product is contaminated. This is not a failure of laboratory technique; it is an inherent property of the product matrix. This is precisely why B&F validation is mandatory.
Part II: The Membrane Filtration Method
Membrane filtration is the compendial gold standard for sterility testing of filterable products and is mandatory or strongly preferred for products with antimicrobial properties. The procedure has three sequential stages:
- Filtration. The product is passed through a sterile closed membrane filter with a nominal pore size of ≤0.45 μm. The membrane acts as a selective physical barrier: microorganisms are retained on the filter surface while the product’s dissolved components — including inhibitory substances — pass through the membrane into the waste filtrate.
- Washing (rinsing). The filter is rinsed with multiple volumes of a sterile diluent containing an appropriate inactivating agent (e.g., lecithin and polysorbate 80 for quaternary ammonium preservatives; sodium thiosulfate for halogens). Each wash volume physically removes residual product from the filter surface and the inactivating agents chemically neutralize any remaining antimicrobial activity. The number of washes is determined and validated during method suitability testing — insufficient washing is one of the most common causes of B&F test failure.
- Culture incubation. After washing, the filter membrane is aseptically transferred into — or the filter assembly is directly immersed in — the FTM and SCDM/TSB vessels. The filter, carrying any retained microorganisms, is now in contact with clean, growth-promoting media free of inhibitory substances. The vessels are incubated for 14 days and examined for turbidity.
Because membrane filtration allows larger product volumes to be tested (the entire volume of a large-volume parenteral can be filtered through a single assembly) and physically separates microorganisms from the inhibitory matrix, it provides superior sensitivity and reliability compared to direct inoculation for the vast majority of pharmaceutical liquid products.
Part III: Method Suitability — Bacteriostasis and Fungistasis (B&F) Validation
Before any sterility test can be performed on a finished product in a routine, regulatory-compliant context, the chosen method must be validated through bacteriostasis and fungistasis (B&F) testing — also called method suitability testing under USP <71>. B&F testing answers a single, critical question: can this test system actually detect contamination in this specific product?
No matter how rigorously the test is executed, a sterility test that cannot detect low-level contamination in the product it is testing is scientifically worthless. B&F testing is the regulatory proof that the method works.
The six USP <71> test organisms
USP <71> specifies six organisms that must all be challenged during B&F testing. These organisms were selected to represent the principal categories of potential pharmaceutical contaminants:
- Staphylococcus aureus ATCC 6538 — aerobic gram-positive bacterium; represents common skin/environmental contamination
- Pseudomonas aeruginosa ATCC 9027 — aerobic gram-negative bacterium; represents challenging gram-negative organisms and water-associated contaminants
- Bacillus subtilis ATCC 6633 — aerobic spore-forming gram-positive bacterium; represents heat-resistant spore-formers
- Clostridium sporogenes ATCC 19404 — anaerobic spore-forming bacterium; represents the critical anaerobic category requiring FTM detection
- Candida albicans ATCC 10231 — yeast; represents fungal contamination
- Aspergillus brasiliensis ATCC 16404 — mold; represents filamentous fungal contamination (formerly classified as A. niger)
The B&F procedure and acceptance criteria
Each of the six test organisms is separately inoculated into the test system at a low inoculum of not more than 100 colony-forming units (CFU). These inoculated systems are incubated alongside control samples (inoculated medium without product) for a maximum of 5 days. The test method is considered suitable — and B&F testing is passed — if detectable growth of each organism is observed within the incubation period in the product-containing system at a level comparable to the product-free control.
If growth of any of the six organisms is suppressed in the product-containing system relative to the control, B&F testing fails for that organism. For direct inoculation, this failure means the method cannot be used — the laboratory must either neutralize the antimicrobial activity through chemical means or switch to membrane filtration. For membrane filtration, failure means the rinsing protocol is insufficient — more wash volumes, stronger inactivating agents, or alternative filter materials must be validated until the method passes.
B&F testing must be repeated whenever the product formulation changes, the manufacturing process changes significantly, or a new supplier of culture media or filter assemblies is introduced.
Sterility Testing vs. Bioburden Testing: Understanding the Difference
Sterility testing and bioburden testing are both microbiological quality tests for pharmaceutical products, but they serve fundamentally different purposes and are performed at different stages of the manufacturing process.
- Bioburden testing (USP <61>, ISO 11737-1) quantifies the total number of viable microorganisms present on or in a product before terminal sterilization. Bioburden data is used to validate sterilization processes — the sterilization cycle must be capable of achieving the required sterility assurance level (SAL of 10⁻⁶) starting from the measured pre-sterilization bioburden. Bioburden testing is a quantitative measure.
- Sterility testing (USP <71>) is a qualitative test confirming the absence of viable microorganisms in the final, sterilized product. It is performed on finished product samples after sterilization and is the compendial release criterion. Sterility testing is pass/fail — growth or no growth.
The two tests are complementary: bioburden testing validates the process; sterility testing confirms the outcome. Neither test is a substitute for the other. Well-designed pharmaceutical quality assurance programs include both, alongside process validation and environmental monitoring, as part of a comprehensive sterility assurance system.
Rapid and Alternative Sterility Testing Methods
The 14-day incubation period mandated by USP <71> is a significant operational constraint — particularly for short-shelf-life products such as radiopharmaceuticals, autologous cell therapies, and compounded sterile preparations where the product may expire before results are available. USP General Chapter <1071> Rapid Microbiological Methods provides a regulatory framework for qualifying alternative sterility testing methods that can produce results significantly faster than the compendial 14-day period.
- ATP bioluminescence. Detects microbial ATP (adenosine triphosphate) as a proxy for viable organisms. Can provide results within hours of sample processing. Used extensively in environmental monitoring and is gaining ground in product sterility applications.
- Flow cytometry. Counts and classifies individual cells using laser-based detection. Can detect and enumerate microorganisms rapidly with high sensitivity. Commercially available rapid sterility systems (e.g., BacT/ALERT, BACTEC) use growth-based detection that shortens positive detection time from 14 days to as little as 2-5 days for actively growing organisms.
- PCR-based detection. Molecular methods targeting conserved microbial DNA (16S rRNA genes for bacteria, ITS regions for fungi) can provide highly sensitive detection in hours. Regulatory acceptance of PCR-based sterility testing requires extensive validation demonstrating equivalence to the compendial method.
Regulatory acceptance of alternative methods under USP <1071> requires a formal validation study demonstrating that the alternative method is at least as sensitive as USP <71> for the specific product and that it does not introduce new false-positive or false-negative risks. FDA has accepted alternative sterility testing methods in a number of product-specific regulatory submissions, particularly for cell and gene therapy products.
Environmental Requirements: ISO Class 5, Isolators, and Cleanrooms
Sterility testing must be performed in an ISO Class 5 (Grade A) environment — a cleanroom classification characterized by a maximum of 3,520 particles ≥0.5 μm per cubic meter of air. This specification reflects the requirement that the test environment itself must not introduce contamination that could be attributed to the environment rather than the product.
Two primary facility configurations meet this requirement:
- Restricted Access Barrier Systems (RABS) and Isolators. Pharmaceutical-grade isolators provide a physically enclosed ISO Class 5 environment with full HEPA filtration and positive pressure. They offer superior protection against environmental contamination and operator-induced contamination compared to open cleanrooms. Isolators are the preferred sterility testing environment for finished product release testing.
- Laminar Air Flow (LAF) hoods in ISO Class 7/8 cleanrooms. Vertical or horizontal LAF hoods provide localized ISO Class 5 conditions within a supporting cleanroom infrastructure. Personnel must be qualified and trained in aseptic technique to minimize the risk of false-positive contamination events.
Environmental monitoring of the sterility testing facility is itself a regulatory requirement — viable and non-viable particle counts, surface monitoring, and personnel monitoring must be performed regularly, and results trended. A contamination event in the testing environment can trigger an investigation that may require invalidation and repeat testing of affected batches.
Outsourcing Sterility Testing to a Contract Laboratory
Establishing and maintaining an in-house sterility testing capability — ISO Class 5 environment, qualified personnel, validated methods, environmental monitoring program, and the regulatory infrastructure to support batch release — represents a substantial investment. For many pharmaceutical manufacturers, particularly smaller companies, CMOs, and organizations in development phases, outsourcing sterility testing to an accredited contract laboratory is the most practical and cost-effective approach.
Contract sterility testing laboratories in the ContractLaboratory.com network provide critical expertise across several dimensions:
- Inactivating agent selection and validation. Determining the correct chemical neutralizing agents (lecithin, polysorbate 80, specific enzymes) for a novel formulation requires microbiological expertise and method development work. Contract laboratories with broad experience across pharmaceutical product types can expedite this process significantly.
- B&F test development and troubleshooting. If the initial B&F test fails, an experienced laboratory will have a systematic approach to modifying the method — adjusting sample-to-medium ratios, increasing wash volumes, changing filter materials, or adding combination inactivating agents — to achieve a validated, compliant method without unnecessary delays to the product development timeline.
- Regulatory documentation. Sterility test results submitted in regulatory dossiers must be accompanied by comprehensive method validation documentation. Experienced contract laboratories maintain templated validation packages compliant with FDA, EMA, and ICH expectations.
- GMP-compliant QMS. All sterility testing results generated for product release must be produced under a validated Quality Management System (QMS). Accredited contract laboratories maintain cGMP-compliant documentation, change control, deviation management, and out-of-specification (OOS) investigation procedures.
For organizations requiring pharmaceutical sterility testing, medical device sterility testing, or biologics testing, ContractLaboratory.com connects you with accredited cleanroom microbiology laboratories. Submit a sterility testing request to receive proposals from qualified laboratories, or contact our team for guidance on finding the right testing partner.
Frequently Asked Questions About Sterility Testing
USP General Chapter <71> is the United States Pharmacopeia’s compendial standard for sterility testing of pharmaceutical products, medical devices, and biologics intended for human or animal use. It specifies two validated test methods (membrane filtration and direct inoculation), two culture media (FTM for anaerobes; SCDM/TSB for aerobes and fungi), a 14-day minimum incubation period, and mandatory method suitability (B&F) testing. USP <71> is harmonized with European Pharmacopoeia Chapter 2.6.1 and the Japanese Pharmacopoeia, meaning the core requirements are consistent across all three major regulatory markets.
Both methods achieve the same goal — detecting microbial contamination in a product — but through different mechanisms. Direct inoculation adds the test article directly into culture media; it is simpler but risks false-negative results if the product contains antimicrobial substances that inhibit growth. Membrane filtration passes the product through a ≤0.45 μm membrane, retaining microorganisms while the product and its inhibitory substances flow through; the membrane is then rinsed with inactivating agents and cultured. Membrane filtration is the regulatory gold standard for aqueous products and any product with antimicrobial properties. Direct inoculation is preferred for medical devices and viscous products not amenable to filtration.
The 14-day minimum incubation period is required because some viable contaminating microorganisms — particularly slow-growing fungi, spore-forming anaerobes, and fastidious bacteria — may require extended incubation before producing detectable turbidity in culture media. Shortening the incubation period risks releasing contaminated product whose contamination is not yet visible. Cultures are observed visually at multiple intervals (typically days 3, 5, 7, and 14); a result is only reported as passing if no growth is observed throughout the full 14-day period.
Bacteriostasis and fungistasis (B&F) testing — also called method suitability testing under USP <71> — is a mandatory validation procedure that proves the chosen sterility test method can actually detect contamination in the specific product being tested. Six USP-specified organisms (S. aureus, P. aeruginosa, B. subtilis, C. sporogenes, C. albicans, and A. brasiliensis) are each inoculated into the test system at ≤100 CFU. If all six organisms show detectable growth within 5 days despite the presence of the product matrix, the method passes B&F validation. If any organism is suppressed, the method must be modified and retested before it can be used for product release testing.
Bioburden testing quantifies the number of viable microorganisms present in or on a product before terminal sterilization — it is a quantitative measure used to validate sterilization processes. Sterility testing is performed on finished, sterilized product and is qualitative — it confirms the absence (pass) or presence (fail) of any viable microorganisms after sterilization. The two tests serve different regulatory purposes: bioburden supports process validation, while sterility testing is a product release criterion. Both are components of a comprehensive pharmaceutical sterility assurance program, alongside process validation and environmental monitoring.
Sterility testing is required for all pharmaceutical products and medical articles labeled as sterile and intended for parenteral administration or contact with sterile body spaces. This includes injectable drugs (IV solutions, injections), ophthalmic products, sterile powders, medical devices (implants, catheters, surgical instruments), biologics (monoclonal antibodies, vaccines, cell therapies), compounded sterile preparations under USP <797>, radiopharmaceuticals, and tissue-based products regulated under 21 CFR Part 1271. The specific test requirements (number of samples, volumes tested) are defined in USP <71> Tables 2 and 3 based on batch size and container volume.
Establishing in-house sterility testing capability requires an ISO Class 5 environment, validated test methods for each product, a cGMP-compliant quality management system, and qualified, regularly re-qualified personnel — a substantial and ongoing investment. Contract laboratories that specialize in sterility testing maintain all of this infrastructure and expertise permanently, often across a wider range of product types and regulatory markets than an in-house lab would encounter. For manufacturers in early development, for CMOs managing diverse client portfolios, and for any organization seeking to reduce fixed costs without compromising regulatory compliance, outsourcing to an accredited contract sterility testing laboratory is typically the most efficient and reliable approach.
Conclusion
Sterility testing under USP <71> is a zero-tolerance discipline — a single contamination event means batch rejection, regulatory scrutiny, and potential patient safety risk. Understanding the method selection logic (membrane filtration for antimicrobial products and large volumes; direct inoculation for devices and non-filterable matrices), the non-negotiable role of B&F method suitability validation, and the environmental and personnel requirements that underpin a valid test is essential for any pharmaceutical manufacturer, medical device company, or biotech firm developing or releasing sterile products.
The distinction between sterility testing and bioburden testing, the growing regulatory pathway for rapid alternative methods under USP <1071>, and the clear advantages of partnering with an experienced contract laboratory are all practical considerations that shape how sterility assurance programs are designed and executed.